

elf atochem

ATO

"Contains NO PCBs"
ELF ATOCHEM NORTH AMERICA, INC.
900 First Avenue, P.O. Box 1536
King of Prussia, PA 19406-0018
Tel: 215-337-6500

92 AUG 31 PM 1:38

A

August 13, 1992



8EHQ-92-12823
INIT 08/31/92

CERTIFIED MAIL

RETURN RECEIPT REQUESTED

88920010889
8EHQ-92-12823

Document Processing Center (TS-790)
Office of Toxic Substances
U.S. Environmental Protection Agency
401 M St., S.W.
Washington, D.C. 20460



88920010889

Attn: Section 8(e) Coordinator (CAP Agreement)

RE: Report Submitted Pursuant to the TSCA Section 8(e)
Compliance Audit Program

CAP Identification Number: 8ECAP-0026

Dear Sir/Madam:

Pursuant to the Toxic Substances Control Act (TSCA) Section 8(e) Compliance Audit Program and the Agreement for TSCA Section 8(e) Compliance Audit Program (CAP Agreement) executed by Elf Atochem North America Inc. (Atochem) and Environmental Protection Agency (EPA), Atochem is submitting the enclosed acute oral toxicity in rats study to the EPA. This study does not involve effects in humans.

Nothing in this letter or the enclosed study report is considered confidential business information of Atochem.

The enclosed study report provides information on the chemical t-octyl mercaptan. Its exact chemical name is 2,4,4-trimethyl-2-pentanethiol and its CAS number is 141-59-3.

The title of the enclosed study report is t-Octyl Mercaptan Lot No. 101-TO-68, Acute Toxicity Studies. This report consists of three studies. The following is a summary of the adverse effects observed in the acute oral toxicity study.

Tertiary octyl mercaptan, dissolved in sesame oil, was administered by gavage to a group of ten male Wistar rats at a dosage of 50 mg/kg. Nine of the ten test animals died within 143 minutes.

10/31/94

TSCA CAP
t-Octyl Mercaptan
August 13, 1992
Page Two

The following are the EPA Document Control Numbers of Atochem's previous TSCA Section 8(e) notices on the subject chemical:

8EHQ-1291-1851 INIT
8EHQ-1291-1850 INIT
8EHQ-1291-1852 INIT
8EHQ-1291-1853 INIT

Further questions regarding this submission may be directed to me at 215 337-6892.

Sincerely,



C.H. Farr, PhD, DABT
Manager, Product Safety
and Toxicology

Enclosures

RE: T-OCTYL MERCAPTAN Lot No. 101-TO-68. CAS Registry Number 141-59-3

A CLEAR, COLORLESS, MALODOROUS LIQUID; AMBIENT SP GR = 0.838.

- SUMMARY. (1) AN ORAL DOSE OF 50 MG/KG CAUSED DEATH OF NINE OF TEN RATS.
(2) INHALATION OF 2 MG/LITER CAUSED DEATH OF ALL OF TEN RATS.
(3) SKIN CONTACT WITH 200 MG/KG WAS NONTOXIC TO ANY OF TEN RABBITS.

THIS PRODUCT IS CLASSIFIED AS A CLASS B POISON IN ACCORDANCE WITH DOT 173.343(a) (1) AND (2).

(1) ORAL TOXICITY IN RATS.

METHOD. THE SAMPLE WAS DILUTED WITH SESAME OIL AND ADMINISTERED BY STOMACH TUBE TO TEN ♂ WISTAR RATS WEIGHING 248 TO 288 GRAMS; EACH RAT WAS GIVEN 50 MG/KG. THE SURVIVING ANIMAL WAS OBSERVED FOR FIVE DAYS.

RESULTS. NINE OF THE TEN RATS SUCCUMBED; DEATH TIMES WERE 30, 36, 44, 46, 48, 57, 57, 58 AND 143 MINUTES AFTER INTUBATION. SYMPTOMS WERE INITIAL MUSCULAR SPASMS, VIOLENT CLONIC CONVULSIONS, PROSTRATION AND TERMINAL DYSPNEA.

(2) INHALATION TOXICITY IN RATS.

METHOD. TEN ♂ WISTAR RATS WEIGHING 244 TO 290 GRAMS WERE USED. EACH WAS PLACED IN A STATIC 20-LITER CHAMBER; 0.048 ML (40 MG) OF THE SAMPLE WAS INTRODUCED AND THE CHAMBER SEALED HERMETICALLY. THE ANIMALS WERE OBSERVED UNTIL DEATH.

RESULTS. ALL OF THE RATS SUCCUMBED DURING EXPOSURE; DEATH TIMES WERE 19, 22, 26, 27, 30, 30, 32, 34, 40 AND 49 MINUTES OF VAPOR INHALATION. SYMPTOMS WERE INITIAL MUSCULAR SPASMS, VIOLENT CLONIC CONVULSIONS, PROSTRATION AND TERMINAL DYSPNEA.

(3) DERMAL TOXICITY IN RABBITS.

METHOD. THE FUR WAS CLIPPED FROM THE TRUNKS OF TEN ALBINO RABBITS WEIGHING 1.94 TO 2.67 KG. A DOSE OF 200 MG/KG (0.239 ML/KG) WAS APPLIED TO A MAXIMAL AREA OF THE SKIN OF EACH RABBIT AND COVERED WITH LOOSE, IMPERMEABLE SLEEVES. THE LATTER WERE REMOVED AFTER FOUR HOURS WHEN THE CHARACTERISTIC ODOR OF THE SAMPLE WAS NO LONGER DETECTIBLE. THE ANIMALS WERE KEPT UNDER OBSERVATION FOR FIVE DAYS.

RESULTS. NO SIGNS OF TOXICITY WERE INDUCED BY TREATMENT AND ALL RABBITS SHOWED NORMAL GAINS IN BODY WEIGHT DURING THE PERIOD OF OBSERVATION.

PHARMACOLOGY RESEARCH, INC.

By A. R. Latven
A. R. LATVEN 10/09/70



UNITED STATES ENVIRONMENTAL PROTECTION AGENCY
WASHINGTON, D.C. 20460

C. H. Farr, PhD, DABT
Manager, Product Safety and Toxicology
Atochem North America, Inc.
900 First Avenue
P.O. Box 1536
King of Prussia, Pennsylvania 19406-0018

OFFICE OF
PREVENTION, PESTICIDES AND
TOXIC SUBSTANCES

JAN 12 1995

EPA acknowledges the receipt of information submitted by your organization under Section 8(e) of the Toxic Substances Control Act (TSCA). For your reference, copies of the first page(s) of your submission(s) are enclosed and display the TSCA §8(e) Document Control Number (e.g., 8EHQ-00-0000) assigned by EPA to your submission(s). Please cite the assigned 8(e) number when submitting follow-up or supplemental information and refer to the reverse side of this page for "EPA Information Requests".

All TSCA 8(e) submissions are placed in the public files unless confidentiality is claimed according to the procedures outlined in Part X of EPA's TSCA §8(e) policy statement (43 FR 11110, March 16, 1978). Confidential submissions received pursuant to the TSCA §8(e) Compliance Audit Program (CAP) should already contain information supporting confidentiality claims. This information is required and should be submitted if not done so previously. To substantiate claims, submit responses to the questions in the enclosure "Support Information for Confidentiality Claims". This same enclosure is used to support confidentiality claims for non-CAP submissions.

Please address any further correspondence with the Agency related to this TSCA 8(e) submission to:

Document Processing Center (7407)
Attn: TSCA Section 8(e) Coordinator
Office of Pollution Prevention and Toxics
U.S. Environmental Protection Agency
Washington, D.C. 20460-0001

EPA looks forward to continued cooperation with your organization in its ongoing efforts to evaluate and manage potential risks posed by chemicals to health and the environment.

Sincerely,

Terry R. O'Bryan
Terry R. O'Bryan
Risk Analysis Branch

Enclosure

12823 A



Recycled/Recyclable
Printed with Soy/Canola Ink on paper that
contains at least 50% recycled fiber

Triage of 8(e) Submissions

Date sent to triage: JAN 30 1995

NON-CAP

CAP

Submission number: 12823A

TSCA Inventory:

Y N D

Study type (circle appropriate):

Group 1 - Dick Clements (1 copy total)

ECO AQUATO

Group 2 - Ernie Falke (1 copy total)

ATOX SBTOX SEN w/NEUR

Group 3 - Elizabeth Margosches (1 copy each)

STOX CTOX EPI RTOX GTOX
STOX/ONCO CTOX/ONCO IMMUNO CYTO NEUR

Other (FATE, EXPO, MET, etc.): _____

Notes:

THIS IS THE ORIGINAL 8(e) SUBMISSION; PLEASE REFILE AFTER TRIAGE DATABASE ENTRY

For Contractor Use Only	
entire document: <u>0</u> 1 2 pages <u>1</u>	pages <u>1-3</u>
Notes:	
Contractor reviewer: <u>LPS</u>	Date: <u>12-1-94</u>

CECATS/TRIAGE TRACKING DBASE ENTRY FORM

CECATS DATA: 12823
 Submission # BEHQ: 0892-10009 SEQ. A

TYPE: INT SUPP FLWP

SUBMITTER NAME: ELF Atochem North
 America, Inc.

INFORMATION REQUESTED: FLWP DATE:

- 0501 NO INFO REQUESTED
- 0502 INFO REQUESTED (TECH)
- 0503 INFO REQUESTED (VOL. ACTIONS)
- 0504 INFO REQUESTED (REPORTING RATIONALE)

DISPOSITION:

- 0639 REFER TO CHEMICAL SCREENING
- 0678 CAP NOTICE

VOLUNTARY ACTIONS:

- 0401 NO ACTION REPORTED
- 0402 STUDIES PLANNED/IN PROGRESS
- 0403 NOTIFICATION OF WORKER CONCERNS
- 0404 LABEL/MSDS CHANGES
- 0405 PROCESS/HANDLING CHANGES
- 0406 APP/USE DISCONTINUED
- 0407 PRODUCTION DISCONTINUED
- 0408 CONFIDENTIAL

SUB. DATE: 08/13/92 DATE: 08/31/92 CSRAD DATE: 10/31/94

CHEMICAL NAME:

CAS#

141-59-3

INFORMATION TYPE:	P F C	INFORMATION TYPE:	P F C	INFORMATION TYPE:	P F C
0201 ONCO (HUMAN)	01 02 04	0216 EPI/CLIN	01 02 04	0241 IMMUNO (ANIMAL)	01 02 04
0202 ONCO (ANIMAL)	01 02 04	0217 HUMAN EXPOS (PROD CONTAM)	01 02 04	0242 IMMUNO (HUMAN)	01 02 04
0203 CELL TRANS (IN VITRO)	01 02 04	0218 HUMAN EXPOS (ACCIDENTAL)	01 02 04	0243 CHEM/PHYS PROP	01 02 04
0204 MUTA (IN VITRO)	01 02 04	0219 HUMAN EXPOS (MONITORING)	01 02 04	0244 CLASTO (IN VITRO)	01 02 04
0205 MUTA (IN VIVO)	01 02 04	0220 ECO/AQUA TOX	01 02 04	0245 CLASTO (ANIMAL)	01 02 04
0206 REPRO/TERATO (HUMAN)	01 02 04	0221 ENV. OCC/REL/FATE	01 02 04	0246 CLASTO (HUMAN)	01 02 04
0207 REPRO/TERATO (ANIMAL)	01 02 04	0222 EMER INCI OF ENV CONTAM	01 02 04	0247 DNA DAM/REPAIR	01 02 04
0208 NEURO (HUMAN)	01 02 04	0223 RESPONSE REQEST DELAY	01 02 04	0248 PROD/USE/PROC	01 02 04
0209 NEURO (ANIMAL)	01 02 04	0224 PROD/COMP/CHEM ID	01 02 04	0251 MSDS	01 02 04
0210 ACUTE TOX. (HUMAN)	01 02 04	0225 REPORTING RATIONALE	01 02 04	0299 OTHER	01 02 04
0211 CHR. TOX. (HUMAN)	01 02 04	0226 CONFIDENTIAL	01 02 04		
0212 ACUTE TOX. (ANIMAL)	01 02 04	0227 ALLERG (HUMAN)	01 02 04		
0213 SUB ACUTE TOX (ANIMAL)	01 02 04	0228 ALLERG (ANIMAL)	01 02 04		
0214 SUB CHRONIC TOX (ANIMAL)	01 02 04	0239 METAB/PHARMACO (ANIMAL)	01 02 04		
0215 CHRONIC TOX (ANIMAL)	01 02 04	0240 METAB/PHARMACO (HUMAN)	01 02 04		

TRIAGE DATA: NON-CBI INVENTORY

YES

CAS SR NO

IN TERMINI

ONGOING REVIEW

YES (DROP/REFER)

NO (CONTINUE)

REFER

SPECIES

RAT

RBT

TOXICOLOGICAL CONCERN:

LOW

MED

HIGH

USE:

PRODUCTION:

Behv - 1291-1850, 1851, 1852, 1853

-CPSS- 0606951552

0 0 0 0 0 0 0 0 0 0 0

> <ID NUMBER>

8(E)-12823A

> <TOX CONCERN>

L/M/H

> <COMMENT>

ACUTE ORAL TOXICITY IN MALE RATS IS HIGH CONCERN. ANIMALS WERE DOSED WITH 50 MG/KG OF TEST MATERIAL WITH A MORTALITY RATE OF 9 OUT OF 10. CLINICAL SIGNS INCLUDED INITIAL MUSCULAR SPASMS, VIOLENT CLONIC CONVULSIONS, PROSTRATION, AND TERMINAL DYSPNEA.

ACUTE INHALATION TOXICITY IN MALE RATS IS MEDIUM CONCERN. ANIMALS WERE WERE EXPOSED TO 2 MG/LOF TEST MATERIAL AND ALL DIED (10 OUT OF 10). CLINICAL SIGNS INCLUDED INITIAL MUSCULAR SPASMS, VIOLENT CLONIC CONVULSIONS, PROSTRATION, AND TERMINAL DYSPNEA.

ACUTE DERMAL TOXICITY IN RABBITS IS LOW CONCERN. WHEN 200 MG/KG OF TEST MATERIAL WAS APPLIED TO 10- RABBITS NO CLINICAL SIGNS OF TOXICITY APPEARED AND ALL SHOWED NORMAL WEIGHT GAIN.

\$\$\$\$